. GKT831 achieves marked anti-fibrotic effects in clinically relevant model of advanced cholestatic disease . Interim results of the Phase 2 Clinical Trial with GKT831 in Primary Biliary Cholangitis expected in early ...
. Data Demonstrate Potential of GKT831 to Efficiently Target Cancer Associated Fibroblasts . Interim results of the Phase 2 Trial with GKT831 in Primary Biliary Cholangitis expected in early November 2018 Genkyote ...
Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Pha ...
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today the completion of enrollment in its Phase 2 trial of GKT831 in patients with P ...
Paris, France and Geneva, Switzerland, September 18, 2018 – 07:30am CEST – Servier and GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that GeNeuro has regained worldwide rights ex US and Japan to its lead ...
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GK ...
